ReviewCritical care (London, England)2017
The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature.
Review in Critical care (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 50 citations in OpenAlex.
- Management of post-resuscitation vasoplegic shock: targets, strategies and outcomes.Critical care (London, England) · 2025Review
- Kinetics of Renin Concentrations in Infants Undergoing Congenital Cardiac Surgery.Journal of intensive care medicine · 2025Article
- The use of angiotensin II for the management of distributive shock: expert consensus statements.Journal of anesthesia, analgesia and critical care · 2024Article
- Characterizing the Stability of Angiotensin II in 0.9% Sodium Chloride Using High Performance Liquid Chromatography and Liquid Chromatography Tandem Mass Spectrometry.Hospital pharmacy · 2024Article
- Sepsis Management in the Cardiac Intensive Care Unit.Journal of cardiovascular development and disease · 2023Review
- Reply to: Rethinking Vasopressor Education: The Need to Avoid Teaching the Bare Minimum.ATS scholar · 2023Article
- Article
- The medical treatment of cardiogenic shock.Journal of intensive medicine · 2023Review
- Vasopressors in Septic Shock: The Quest for Refinement.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2022Article
- The Role of Angiotensin II in Poisoning-Induced Shock-a Review.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2022Review
- A Multicenter Observational Cohort Study of Angiotensin II in Shock.Journal of intensive care medicine · 2022Observational
- Vasopressors in septic shock: which, when, and how much?Annals of translational medicine · 2020Review
- Angiotensin II in ECMO patients: a word of caution.Critical care (London, England) · 2019Article
- Article
- Angiotensin in ECMO patients with refractory shock.Critical care (London, England) · 2018Article
- Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II.Critical care medicine · 2018Article
- Angiotensin II for the treatment of vasodilatory shock: enough data to consider angiotensin II safe?Critical care (London, England) · 2018Article
- Angiotensin in Critical Care.Critical care (London, England) · 2018Review
- Angiotensin II: a new therapeutic option for vasodilatory shock.Therapeutics and clinical risk management · 2018Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculatory shock is a common syndrome with a high mortality and limited therapeutic options. Despite its discovery and use in clinical and experimental settings more than a half-century ago, angiotensin II (Ang II) has only been recently evaluated as a vasopressor in distributive shock. We examined existing literature for associations between Ang II and the resolution of circulatory shock.
methodsWe searched PubMed, MEDLINE, Ovid, and Embase to identify all English literature accounts of intravenous Ang II in humans for the treatment of shock (systolic blood pressure [SBP] ≤ 90 mmHg or a mean arterial pressure [MAP] ≤ 65 mmHg), and hand-searched the references of extracted papers for further studies meeting inclusion criteria. Of 3743 articles identified, 24 studies including 353 patients met inclusion criteria. Complete data existed for 276 patients. Extracted data included study type, publication year, demographics, type of shock, dosing of Ang II or other vasoactive medications, and changes in BP, lactate, and urine output. BP effects were grouped according to type of shock, with additional analyses completed for patients with absent blood pressure. Shock was distributive (n = 225), cardiogenic (n = 38), or from other causes (n = 90). Blood pressure as absent in 18 patients.
resultsFor the 276 patients with complete data, MAP rose by 23.4% from 63.3 mmHg to 78.1 mmHg in response to Ang II (dose range: 15 ng/kg/min to 60 mcg/min). SBP rose by 125.2% from 56.9 mmHg to 128.2 mmHg (dose range: 0.2 mcg/min to a 1500 mcg bolus). A total of 271 patients with complete data were determined to exhibit a BP effect which was directly associated with Ang II. Subgroups (patients with cardiogenic, septic, and other types of shock) exhibited similar increases in BP. In patients with absent BP, deemed to be cardiac arrest, return of spontaneous circulation (ROSC) was achieved, and BP increased by an average of 107.3 mmHg in 11 of 18 patients. The remaining seven patients with cardiac arrest did not respond.
conclusionsIntravenous Ang II is associated with increased BP in patients with cardiogenic, distributive, and unclassified shock. A role may exist for Ang II in restoring circulation in cardiac arrest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.